![Theravance, Inc. Logo](http://www.globenewswire.com/en/Attachment/LogoDisplay/213519?filename=213519.jpg&size=2)
Theravance and Merck Sign Cardiovascular Disease Collaboration
October 16, 2012 08:00 ET
|
Theravance, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2012 (GLOBE NEWSWIRE) -- Theravance, Inc. (Nasdaq:THRX) announced today that it has signed a collaboration agreement with Merck, known as MSD outside the United...
![Theravance, Inc. Logo](http://www.globenewswire.com/en/Attachment/LogoDisplay/213519?filename=213519.jpg&size=2)
Theravance and Alfa Wassermann Enter Into Agreement to Develop and Commercialize Velusetrag for Gastroparesis
October 02, 2012 16:05 ET
|
Theravance, Inc.
SOUTH SAN FRANCISCO, Calif. and BOLOGNA, Italy, Oct. 2, 2012 (GLOBE NEWSWIRE) -- Theravance, Inc. (Nasdaq:THRX) and Alfa Wassermann S.p.A. announced today that they have entered into an exclusive...
![Theravance, Inc. Logo](http://www.globenewswire.com/en/Attachment/LogoDisplay/213519?filename=213519.jpg&size=2)
GSK and Theravance Announce FDA Acceptance of FF/VI New Drug Application (NDA) Submission in the US for COPD
September 26, 2012 04:00 ET
|
Theravance, Inc.
LONDON and SOUTH SAN FRANCISCO, Calif., Sept. 26, 2012 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (GSK) and Theravance, Inc. (Nasdaq:THRX) today announced that the New Drug Application (NDA) for the...
![Theravance, Inc. Logo](http://www.globenewswire.com/en/Attachment/LogoDisplay/213519?filename=213519.jpg&size=2)
Theravance to Present at the Morgan Stanley Global Healthcare Conference
August 29, 2012 16:05 ET
|
Theravance, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2012 (GLOBE NEWSWIRE) -- Theravance, Inc. (Nasdaq:THRX) announced today that Rick E Winningham, Theravance's Chief Executive Officer, is scheduled to present at...
![Theravance, Inc. Logo](http://www.globenewswire.com/en/Attachment/LogoDisplay/213519?filename=213519.jpg&size=2)
GSK and Theravance Announce Completion of the Phase III Programme for Once-Daily LAMA/LABA (UMEC/VI) in COPD
August 24, 2012 07:03 ET
|
Theravance, Inc.
LONDON and SOUTH SAN FRANCISCO, Calif., Aug. 24, 2012 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (GSK) and Theravance, Inc. (Nasdaq:THRX) today announced the completion of the phase III programme of an...
![Theravance, Inc. Logo](http://www.globenewswire.com/en/Attachment/LogoDisplay/213519?filename=213519.jpg&size=2)
Theravance Reports Second Quarter 2012 Financial Results
July 31, 2012 16:05 ET
|
Theravance, Inc.
SOUTH SAN FRANCISCO, Calif., July 31, 2012 (GLOBE NEWSWIRE) -- Theravance, Inc. (Nasdaq:THRX) reported today its financial results for the quarter ended June 30, 2012. Revenue for the second quarter...
![Theravance, Inc. Logo](/news-release/logo/213519/0/213519.jpg?lastModified=12%2F09%2F2016%2022%3A47%3A28&size=2)
Theravance to Report Second Quarter 2012 Financial Results on July 31, 2012
July 17, 2012 16:05 ET
|
Theravance, Inc.
SOUTH SAN FRANCISCO, Calif., July 17, 2012 (GLOBE NEWSWIRE) -- Theravance, Inc. (Nasdaq:THRX) announced today that it will release financial results for the period ended June 30, 2012 after market...
![Theravance, Inc. Logo](http://www.globenewswire.com/en/Attachment/LogoDisplay/213519?filename=213519.jpg&size=2)
GSK and Theravance Announce Regulatory Submissions for FF/VI in the US and Europe
July 13, 2012 07:00 ET
|
Theravance, Inc.
LONDON and SOUTH SAN FRANCISCO, Calif., July 13, 2012 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (GSK) and Theravance, Inc. (Nasdaq:THRX) today announced the submission of regulatory applications in the...
![Theravance, Inc. Logo](http://www.globenewswire.com/en/Attachment/LogoDisplay/213519?filename=213519.jpg&size=2)
Theravance Announces Positive Topline Results From TD-1211 Phase 2b Study 0084 for the Treatment of Opioid-Induced Constipation
July 10, 2012 16:05 ET
|
Theravance, Inc.
SOUTH SAN FRANCISCO, Calif., July 10, 2012 (GLOBE NEWSWIRE) -- Theravance, Inc. (Nasdaq:THRX) today announced positive topline results from 0084, the key study in the Phase 2b program evaluating...
![Theravance, Inc. Logo](http://www.globenewswire.com/en/Attachment/LogoDisplay/213519?filename=213519.jpg&size=2)
GSK and Theravance Announce Positive Results From Four Pivotal Phase III Studies for Once-Daily LAMA/LABA (UMEC/VI) in COPD
July 02, 2012 02:06 ET
|
Theravance, Inc.
LONDON and SOUTH SAN FRANCISCO, Calif., July 2, 2012 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE:GSK) and Theravance, Inc. (Nasdaq:THRX) today announced the results of four pivotal phase III...